Rigel Pharmaceuticals (RIGL) Accumulated Expenses (2010 - 2026)

Rigel Pharmaceuticals' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $6.0 million for Q1 2026.

• In Q1 2026, Accumulated Expenses changed 0.25% year-over-year to $6.0 million; the TTM figure through Mar 2026 stood at $6.0 million (changed 0.25% YoY), while the FY2025 annual figure was $11.9 million, up 17.51% from the prior year.
• Accumulated Expenses was $6.0 million for Q1 2026 at Rigel Pharmaceuticals, down from $11.9 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $11.9 million in Q4 2025 to a low of $5.2 million in Q1 2024.
• Historically, Accumulated Expenses has averaged $7.8 million across 5 years, with a median of $7.9 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses dropped 17.06% in 2022, then gained 27.02% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $8.9 million in 2022, then decreased by 2.14% to $8.7 million in 2023, then increased by 16.86% to $10.1 million in 2024, then grew by 17.51% to $11.9 million in 2025, then slumped by 49.56% to $6.0 million in 2026.
• The last three Accumulated Expenses figures came in at $6.0 million (Q1 2026), $11.9 million (Q4 2025), and $10.1 million (Q3 2025), per Business Quant data.